Atea Pharmaceuticals Inc.

03/14/2023 | Press release | Distributed by Public on 03/14/2023 06:23

Low Risk of Drug-Drug Interactions (DDIs) for Bemnifosbuvir (BEM) Based Upon In Vitro Metabolism and Transporter Interaction Studies